Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
The K-LISA™ IKKβ-Inhibitor Screening Kit is designed for rapid in vitro screening of IKKβ inhibitors. The assay is an ELISA-based activity assay that utilizes a 50-amino acid GST-IκBα fusion polypeptide substrate that includes the Ser32 and Ser36 IKKβ phosphorylation sites. The GST-IκBα substrate and IKKβ are incubated in the presence of IKKβ inhibitors in the wells of a Glutathione-Coated 96-Well Plate, which allows for substrate phosphorylation and capture in a single step. The phosphorylated GST-IκBα substrate is detected using an Anti-Phospho IκBα (Ser32/Ser36) antibody, followed by the HRP-Conjugate and color development with TMB Substrate. ELISA Stop Solution is used to stop the color development and the absorbance is read at 450 nm preferably with a reference wavelength of 540-600 nm. The absorbance is directly related to the level of IKKβ activity.
• Spectrophotometer capable of measuring absorbance in 96-well plates at 450 nm, preferably in the dual wavelength mode with a reference wavelength of 540-600 nm.
References
References
Greten, F.R., et al. 2004. Cell118, 285. Baldwin, A.S., 2001. J. Clin. Invest.107, 241. Yamamoto, Y. and Gaynor, R.B., 2001. J. Clin. Invest.107, 135. Karin, M., et al. 2000. Annu. Rev. Immunol.18, 621. Zandi, E., et al. 1997. Cell91, 243.
Greten, F.R., et al. 2004. Cell118, 285. Baldwin, A.S., 2001. J. Clin. Invest.107, 241. Yamamoto, Y. and Gaynor, R.B., 2001. J. Clin. Invest.107, 135. Karin, M., et al. 2000. Annu. Rev. Immunol.18, 621. Zandi, E., et al. 1997. Cell91, 243.
Upon arrival store the IKKΒ, His·Tag®, Human, Recombinant, Spodoptera frugiperda at -70°C and the remaining components at -20°C.
Intended use
The K-LISA™ IKKΒ-Inhibitor Screening Kit is designed for rapid in vitro screening of IKKΒ inhibitors.
Background
IκB kinases, IKKα (also called IKK-1) and IKKβ (IKK-2), are related kinases that play a major role in the activation and regulation of the transcription factor, NF- κB. They are induced by stimuli such as TNFα and IL-1 to phosphorylate Ser32 and Ser36 in IκBα, the regulatory subunit of NF-κB. The phosphorylation of Iκα results in ubiquitination and subsequent degradation in the proteasome. The induced proteolysis of IκBα unmasks the nuclear localization signal within NF-κB, resulting in its rapid migration into the nucleus where it activates the transcription of numerous target genes. The IκB kinase (IKK) complex is composed of three polypeptides: the catalytic subunits, IKKα (IKK-1) and IKKβ (IKK-2), and the regulatory subunit, IKKγ (IKK-3/NEMO). IKKβ appears to be the principal kinase, whereas IKKα is not required for activation of IKK and degradation of IκBα by proinflammatory stimuli.
IKKβ triggers the activation of NF-κB in response to infectious agents and proinflammatory cytokines, making it an attractive drug target for the treatment of inflammatory diseases. For example, it is reported that orally administered small molecule inhibitors of IKKβ lead to reduced incidence and severity of arthritis in a mouse model.
In addition, NF-κB is over-expressed or constitutively activated in many cancer cells where it induces theexpression of anti-apoptotic genes, which correlates with resistance to anticancer therapies. Deletion of IKKβ in intestinal epithelial cells does not result in a decrease inflammation; it leads to a dramatic decrease in tumor incidence without affecting tumor size. This may be linked to increased epithelial apoptosis during tumor
promotion. Deleting IKKβ in myeloid cells, however, results in a significant decrease in tumor size. This deletion diminishes expression of pro-inflammatory cytokines that may serve as tumor growth factors, without affecting apoptosis. Thus, specific inactivation of the IKK/NF-κB pathway in two different cell types can attenuate formation of inflammation-associated tumors in addition to suppressing apoptosis in advanced tumors. Therefore, inhibitors of IKKβ represent potential therapeutics for the treatment of both cancer and inflammation.
Principles of the assay
The K-LISA™ IKKβ-Inhibitor Screening Kit is an ELISA-based activity assay that utilizes a 50-amino acid GST-IκBα fusion polypeptide substrate that includes the Ser³² and Ser³⁶ IKKβ phosphorylation sites. The GST-IκBα substrate and IKKβ His·Tag®, Human, Recombinant, Spodoptera frugiperda are incubated in the presence of IKKβ inhibitors in the wells of a Glutathione-Coated 96-Well Plate, which allows for substrate phosphorylation and capture in a single step. The phosphorylated GST-IκBα substrate is detected using an Anti-Phospho IκBα (Ser³²/Ser³⁶) antibody, followed by the HRP-Conjugate and color development with TMB Substrate. ELISA Stop Solution is used to stop the color development and the absorbance is read at 450 nm preferably with a reference wavelength of 540-600 nm. The absorbance is directly related to the level of IKKβ activity.
Materials provided
• Glutathione Coated 96-well Plate (Kit Component No. JA9125): 1 plate supplied as 12 X 8-well strips • GST-IκBα (IKKβ Substrate) (Kit Component No. JA9127): 1 vial, 15 µg; please see label for lot-specific concentration • Anti-Phospho IκBα (Ser³²/Ser³⁶) (Kit Component No. JA9126): 1 vial, 15 µl • IKKβ, His·Tag®, Human, Recombinant, Spodoptera frugiperda (Kit Component No. 481404): 1 vial, 2.5 µg • Antibody Diluent (Kit Component No. JA7917): 1 bottle, 25 ml • Kinase Assay Buffer (Kit Component No. JA9130): 1 vial, 5 ml, supplied as a 5X solution • ATP/MgCl₂ Mix (Kit Component No. JA7914): 1 vial, 2 ml, supplied as a 5X solution • IKKβ Inhibitor, 500X (Kit Component No. JA9129): 1 vial, 50 µl IKK-2 Inhibitor IV (Cat. No. 401481): supplied as a 1 mM solution in DMSO • Kinase Stop Solution (Kit Component No. KP31517): 1 vial, 5 ml • ELISA 20X Plate Wash Concentrate (Kit Component No. JA1617): 1 bottle, 100 ml • HRP-Conjugate (Kit Component No. JA7643): 1 vial, 100 µl, supplied as a 400X solution • TMB Substrate (Kit Component No. JA1608): 1 bottle, 12 ml, ready to use • ELISA Stop Solution (Kit Component No. JA1616): 1 bottle, 12 ml, 2.5 N H₂SO₄ ready to use • Plate Sealers: 2 each
Materials Required but not provided
• Spectrophotometer capable of measuring absorbance in 96-well plates at 450 nm, preferably in the dual wavelength mode with a reference wavelength of 540-600 nm.
Reagent preparation
Prepare all reagents immediately prior to use. Following reconstitution of the IKKβ, His·Tag®, Human, Recombinant, Spodoptera frugiperda, aliquot and freeze at -70°C. The reconstituted enzyme will lose activity if subjected to more than 3 freeze/thaw cycles. The following table provides reagent preparation instructions to obtain the volume of Working Solutions (WS) required for one 8-well strip.
Table 1: Reagent Preparation
Detailed protocol
1. Remove required number of strips from the Glutathione-Coated 96-Well Plate and place them in the 96-well frame. Return the unused strips to the foil pouch, reseal the entire edge with tape, and store 4°C. 2. Add the following components to designated wells in the specified order:
Table 2: Addition of Assay Components
*Recommendation for screening inhibitors: to estimate the inhibitory effect of investigational drugs or known kinase inhibitors we suggest to conduct experiments as outlined in the table below. Following the table, add the Assay Reagents to each well, mix thoroughly, and initiate the reaction by adding 10 µl of the ATP/MgCl2 Mix.
Table 3: Assay Set-Up
**Alternatively, the source of enzyme can be supplied by the end-user, but titration of the enzyme sample is recommended prior to inhibitor testing.
***Refers to unknown inhibitor diluted to an appropriate working concentration. If the IC50 of the inhibitor is not known titration of inhibitor is necessary.
****Additional optional control samples containing 10 µl of Inhibitor WS may also be included; the volume of H2O must be adjusted to 10 µl for these additional controls.
3. Cover the plate with the Plate Sealer, mix the contents of the wells with a plate shaker or equivalent, and incubate for 30 min at 30°C. 4. Stop the kinase reaction by adding 10 µl Kinase Stop Solution to each well. (Note: alternatively the reaction may also be stopped by discarding the contents of the well). 5. Aspirate contents of the wells and wash the Glutathione-Coated 96-Well-Plate with ELISA Plate Wash 1X using 200 µl/well. Discard the ELISA Plate Wash 1X solution by shaking the contents into a sink and dry the wells by tapping the inverted plate on paper towels. Repeat for a total of 3 washes. 6. Add 100 µl Anti-Phospho IκBα (Ser32/Ser36) WS to each well and incubate for 1 h at room temperature. 7. Wash the plate as described in step 5 above. 8. Add 100 µl HRP-Conjugate WS to each well and incubate for 1 h at room temperature. 9. Wash the plate as described in step 5 above. 10. Add 100 µl TMB Substrate to each well and incubate for 10-20 min at room temperature. 11. Add 100 µl ELISA Stop Solution to each well and read the absorbance at 450 nm, preferably with a reference wavelength set at 540-600 nm.
Assay characteristics and examples
Figure 1: Enzyme Activity of Purified Recombinant IKKΒ
Typical results obtained when using purified recombinant IKKΒ in the absence of inhibitors. The activity of IKKΒ, His·Tag®, Human, Recombinant, Spodoptera frugiperda (Cat. No. 481404) was measured as outlined in the Detailed Protocol. Please note that the specific activity of the enzyme may vary from lot to lot.
Figure 2: Inhibition of IKKΒ Activity by IKKΒ Inhibitor IV
IKKΒ, His·Tag®, Human, Recombinant, Spodoptera frugiperda (Cat. No. 481404) (5 ng; please note that the specific activity of the enzyme may vary from lot to lot) was incubated in the presence of increasing concentrations of IKK-2 Inhibitor IV (Cat. No. 401481) and 10 µM ATP and the activity was measured as outlined above in the Detailed Protocol.
Figure 3: Inhibition of IKKΒ Activity by Staurosporine
IKKΒ, His·Tag®, Human, Recombinant, Spodoptera frugiperda (Cat. No. 481404) (1.5 ng) was incubated in the presence of increasing concentrations of Staurosporine (Cat. No. 569397) and 10 µM ATP and the activity was measured as outlined above in the Detailed Protocol.
Assay Range
5-10 ng
Registered Trademarks
Calbiochem® and His·Tag® are registered trademarks of EMD Chemicals, Inc. K-LISA™ S·Tag™, and Interactive Pathways™ are trademarks of EMD Chemicals, Inc.